Want to see INVA full AI Analyst Report?
INVA Stock Chart & Stats
$21.44
-$0.14(-0.65%)
At close: 4:00 PM EDT
$21.44
-$0.14(-0.65%)
Day’s Range― - ―
52-Week Range$16.52 - $25.15
Previous Close$21.3
Volume624.27K
Average Volume (3M)833.51K
Market Cap
$1.50B
Enterprise Value$1.36K
Total Cash (Recent Filing)$579.06M
Total Debt (Recent Filing)$269.66M
Price to Earnings (P/E)4.3
Beta0.16
Next Earnings
Nov 11, 2026EPS Estimate
0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.87
Shares Outstanding72,245,480
10 Day Avg. Volume689,867
30 Day Avg. Volume833,514
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)3.17
P/FCF Ratio7.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$40.67Price Target Upside89.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)2.74
Revenue Forecast (FY)$445.26M
Bulls Say, Bears Say
Bulls Say
High Cash GenerationConsistently strong operating and free cash flow indicate durable earnings quality and internal funding for R&D, acquisitions, or dividends. High cash conversion limits reliance on external financing and supports strategic flexibility over the next 2–6 months and beyond.
De-risked Balance SheetMaterial debt reduction and a larger equity base strengthen solvency and lower refinancing risk, improving financial flexibility. This makes the company better positioned to fund pipeline development or opportunistic investments without stressing liquidity.
Strategic Diversification: LYNX And Licensing DealsOwning the LYNX platform and launching Nortiva creates a durable product-development avenue beyond royalties. Combined with licensing deals (e.g., Dr. Reddy’s for XACDURO), this expands addressable markets and creates multiple, long‑term commercial and milestone revenue streams.
Bears Say
Earnings VolatilityLarge swings in margins suggest earnings are influenced by non‑recurring items or timing of investment gains, making forward cash flows less predictable. This undermines near‑term planning for capital allocation and could affect sustained payout or reinvestment policies.
Concentrated Royalty RelianceReliance on royalties from a few partnered respiratory franchises concentrates revenue risk. Long‑term cash generation depends on partners' commercialization, formulary access, and competitive dynamics, which Innoviva cannot fully control.
Historical Leverage Variability & Data InconsistencyPast elevated leverage cycles plus inconsistencies in reported leverage metrics increase uncertainty about financial resilience under stress. This can complicate credit planning and raise refinancing or covenant risk during adverse periods.
Innoviva News
INVA FAQ
What was Innoviva’s price range in the past 12 months?
Innoviva lowest stock price was $16.52 and its highest was $25.14 in the past 12 months.
What is Innoviva’s market cap?
Innoviva’s market cap is $1.50B.
When is Innoviva’s upcoming earnings report date?
Innoviva’s upcoming earnings report date is Nov 11, 2026 which is in 89 days.
How were Innoviva’s earnings last quarter?
Innoviva released its earnings results on Aug 05, 2026. The company reported -$1.14 earnings per share for the quarter, missing the consensus estimate of $0.436 by -$1.576.
Is Innoviva overvalued?
According to Wall Street analysts Innoviva’s price is currently Undervalued.
Does Innoviva pay dividends?
Innoviva pays a Quarterly dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Innoviva dividends here
What is Innoviva’s EPS estimate?
Innoviva’s EPS estimate is 0.51.
How many shares outstanding does Innoviva have?
Innoviva has 72,245,480 shares outstanding.
What happened to Innoviva’s price movement after its last earnings report?
Innoviva reported an EPS of -$1.14 in its last earnings report, missing expectations of $0.436. Following the earnings report the stock price went up 2.925%.
Which hedge fund is a major shareholder of Innoviva?
Currently, no hedge funds are holding shares in INVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innoviva Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.67 (89.68% Upside)
$40.67 (89.68% Upside)
Blogger Sentiment
Bullish
INVA Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 165.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
27.68%
Trailing 12-Months
Company Description
Innoviva
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
INVA Stock 12 Month Forecast
Average Price Target
$40.67
▲(89.68% Upside)
Technical Analysis
Ownership Overview
1.28% Insiders
22.33% Mutual Funds
4.84% Other Institutional Investors
38.36% Public Companies and Individual Investors